Cancer – the emperor of all maladies

1 in 2 people will develop

cancer in their lifetime

CANCER RESEARCH UK | CITY OF LONDON CENTRE

UCL • King's • Barts • Crick

Current sector status

CANCER RESEARCH UK | CITY OF LONDON CENTRE

UCL • King's • Barts • Crick

- Chemotherapy is still the standard of care
- A lot of cancers have still a very poor outcome
- Several tumour types with large patient population have persistently unmet needs
- Best outcomes have improved due to early detection

So, why is cancer so hard to treat?



Tumour evolution & heterogeneity





Rationale





Context: Tumour evolutionary framework

Focus

Development of biological therapies to increase **long term survival.**

Interplay between biological therapies and other precision approaches to cancer.

Goal

Novel combination approaches with enhanced potency and selectivity.

CANCER RESEARCH UK | CITY OF LONDON CENTRE

UCL • King's • Barts • Crick

A CRUK Centre of excellence in biotherapeutics through scale, co-operation and shared vision

CANCER RESEARCH UK | KING'S HEALTH PARTNERS CENTRE

KING'S College LONDON

CANCER RESEARCH UK | UCL CENTRE

UCL

CANCER RESEARCH UK | CITY OF LONDON CENTRE

UCL • King's • Barts • Crick

CANCER RESEARCH UK | BARTS CENTRE

Queen Mary University of London

Barts and The London

THE FRANCIS CRICK INSTITUTE



Programme 1

Developing biological therapies



Programme 2

Cross-disciplinary approaches enhancing biotherapeutics

Programme 3

Cancer evolution and tumour heterogeneity

Paediatrics

CANCER RESEARCH UK | CITY OF LONDON CENTRE

UCL • King's • Barts • Crick

Sector major disruptive trends

- New cell and gene therapies
- Immuno-oncology combination therapies
- Precision medicine
- Diagnostic testing/Biomarkers

Collaborations

CANCER RESEARCH UK | CITY OF LONDON CENTRE

UCL • King's • Barts • Crick

Cell therapy/CarT programme	Imaging	Datasets analysis
• Vector production • Cell manufacturing	• New tracers • New technologies • Cheaper	• Markers • Analysis Software

https://www.colcc.ac.uk/